Cambridge Open Engage home
What is Cambridge Open Engage?
How to Submit
Browse
About
News [opens in a new tab]

Synthetic Studies on the Indane SHIP1 Agonist AQX-1125.

22 July 2021, Version 1
Working Paper
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

A new synthetic route to the SHIP1 agonist AQX-1125 has been developed. This sequence utilizes a hydroxy-acid intermediate which allows for ready differentiation of the C6 and C7 positions. The role of the C17 alkene in the biological activity of the system is also investigated, and this functional group is not required for SHIP1 agonist activity.

Keywords

steroid
SHIP1
agonist
indane
synthesis

Supplementary materials

Title
Description
Actions
Title
AQXpaper-SI
Description
Experimental procedures, new compound characterization data, and NMR spectra.
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.

Version History

Jul 22, 2021 Version 1

Metrics

707
274
0
Views
Downloads
Citations

License

CC logo
CC
BY logo
BY
NC logo
NC
ND logo
ND
The content is available under CC BY NC ND 4.0 [opens in a new tab]

DOI

10.26434/chemrxiv-2021-vdnql
D O I: 10.26434/chemrxiv-2021-vdnql [opens in a new tab]

Funding

National Institute on Aging
RF1AG059717
National Science Foundation
CHE1659775

Author’s competing interest statement

S.D., S. F-D., W.G.K. and J.D.C. have patents on small molecules targeting of SHIP1 and SHIP2 in disease. The other authors have no conflicts to disclose.

Ethics

The author(s) have declared ethics committee/IRB approval is not relevant to this content

Share